Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization

Trial Profile

Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization

Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs PLX PAD (Primary)
  • Indications Ischaemia; Peripheral arterial disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms PACE
  • Sponsors Pluristem Therapeutics
  • Most Recent Events

    • 18 Sep 2017 According to a Pluristem Therapeutics media release, the European Medicines Agency (EMA) has included PLX-PAD in its Adaptive Pathways program. Positive results from an interim analysis following treatment of half (125) of the study's population may lead to early conditional marketing authorization.
    • 11 Sep 2017 According to a Pluristem Therapeutics media release, a company is expecting to have 40 active sites worldwide by the end of 2017.
    • 11 Sep 2017 According to a Pluristem Therapeutics media release, a comapny is currently enrolling patients the U.S., United Kingdom, Germany and Austria for the treatment of Critical Limb Ischemia.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top